M&A - Eli Lilly - Verve Therapeutics

Track this case file

Indianapolis-based pharmaceutical giant Eli Lilly will commence a tender offer to acquire all of the outstanding shares of Boston-based Verve for a purchase price of $10.50 per share in cash, or about $1 billion. Lilly will acquire any shares of Verve that are not tendered in the initial offer through a second step merger at the same consideration as paid in the tender offer. Verve Therapeutics is a clinical-stage company developing genetic medicines for cardiovascular disease. The deal is expected to close in Q3 of 2025. Eli Lilly is traded on the New York Stock Exchange and Verve is traded on Nasdaq.

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login